Skip to content

DBV Technologies DBVT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$536.45M+6.0%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1B+3.7%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$2.35B+1.6%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$4.38B+19.6%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$2.68B+66.8%
Alumis Inc. logo
Alumis Inc.ALMS
$1.56B+68.8%

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+269%
Enterprise value$700.21M+188%
P/S159.6×+89.0×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's additional paid-in capital?
DBV Technologies (DBVT) reported additional paid-in capital of $625.6M in Q1 2026.
How has DBV Technologies's additional paid-in capital changed year-over-year?
DBV Technologies's additional paid-in capital increased by 97.2% year-over-year, from $317.31M to $625.6M.
What is the long-term trend for DBV Technologies's additional paid-in capital?
Over 5 years (2020 to 2025), DBV Technologies's additional paid-in capital has grown at a -14.0% compound annual growth rate (CAGR), from $1.15B to $541.3M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.